FDA panel votes against GLP-1 therapy from former diabetes unicorn Intarcia

By STAT News
| September 22, 2023

An advisory panel to the FDA unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA twice rejected the implant.

Full story

#1

Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...

Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...